Pilot Awards
The Frontiers Pilot Program provides funding for early- and mid-career investigators to complete one-year long, impactful, innovative, collaborative clinical and translational projects that will support applications for subsequent externally funded larger studies. The Frontiers Pilot Program has two major goals: 1. to boost emerging investigators’ research programs to develop critical preliminary data in support of future applications, including studies leading to trials of promising treatments, interventions, devices, or novel diagnostic or analytic approaches; and 2. to support research that addresses clinical challenges pertinent to historically-underserved and excluded populations and communities in the Frontiers catchment area of Kansas and Western Missouri and that in so-doing, can be applied to the general population.
Frontiers CTSI membership is required prior to submitting an application. Become a member and learn about member benefits.
Lauren S. Aaronson Frontiers Pilot Program
The Lauren S. Aaronson (LSA) Frontiers Clinical and Translational Research Pilot Program provides grant funding and other support to grow interdisciplinary, investigator-initiated clinical and translational research across a broad range of scientific disciplines. The objective of this pilot program is to support new and innovative ideas that will lead to externally funded awards.
Up to three awards are issued annually for up to $50,000 each.
LSA Research Priority Areas
Pilot projects are encouraged to focus on translational science, i.e., understanding a scientific or operational principle underlying a step of the translational process with the goal of developing generalizable principles to accelerate translational research.
NCATS definitions:
- Translation: The process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and communities – from diagnostics, preventions, and treatments to medical procedures and behavioral changes.
- Translational Research: The endeavor to traverse a particular step of the translational process for a particular target or disease.
- Translational Science: The field of investigation focused on understanding the scientific and operational principles underlying each step of the translational process.
Where translational research focuses on advancing a step of the translational process for a specific target/disease, translational science seeks to develop, demonstrate, and disseminate generalizable innovations and strategies to improve the process of translational research.
Translational science projects seek to 1) identify and understand barriers that delay progress or limit the quality, impact, or equity of translational research (e.g., clinical trial recruitment, data interoperability, implementation, etc.), and 2) develop innovative solutions (e.g., methods, best practices, tools, technologies) to overcome these barriers. Addressing critical barriers will allow subsequent translational research to accelerate the time from discovery to improved human health. The innovative solutions will have broad applicability to multiple research projects, increasing capacity and efficiency.
Applications directly related to one or more of the following areas will be accepted:
- Processes and programs to understand, support and advance translation, e.g., collaborative structures; diverse workforce development; integration of project management; incentives/credit for team science; incentives/credit for health improvements; education/training (scientific and cultural); biomarker qualification process.
- Data-related improvements and tools, e.g., data interoperability; Electronic Health Records for research; data transparency/release.
- Clinical research improvements and tools, e.g., clinical trial networks; clinical outcome criteria
- (e.g., patient-reported outcomes); clinical diagnostic criteria; contemporary clinical trial designs; single Institutional Review Board (IRB) implementation; regulatory science; shortening time of intervention adoption.
- Clinical study recruitment improvements and tools, e.g., identification, recruitment, engagement and/or retention of populations and/or subpopulations in clinical trials and studies.
- Community and stakeholder engagement.
- Methods to better measure impact on health (or lack thereof).
Application Materials
The deadline for letters of intent has passed for 2024. The 2025 RFA will be released in November, 2024.
Previous Application Materials
Institutional Letter of Support Template
Integrating Special Populations Pilot Award
Integrating Special Populations (ISP) Pilot Program provides grant funding and other support for clinical and translational research across a broad range of scientific disciplines. The objective of this pilot program is to support new and innovative ideas that will lead to externally funded awards. The Frontiers ISP Pilot Award addresses this goal by providing funds to help investigators carry out early-stage research addressing our primary aims 1. Improve health outcomes across the lifespan through multidisciplinary, multi-organizational teams that include patients, caregivers, clinicians, scientists, and other stakeholders and 2. Improve rare disease health outcomes by leveraging input from all stakeholders in study design.
One award is given annually for $25,000.
ISP Research Focus Areas
- Consequences of Maternal-Fetal-Child, and Adolescent disorders and socio-economic disparities on the health of adults and older adults.
- Supporting Transitions of Care from childhood to young adult and adult to older adult.
- Incorporating participants who are older adults or rural residents in drug and other intervention development and testing.
- Addressing unique challenges of rare diseases and improving access to care and other resources for families in rural and underserved communities.
Application Materials
The deadline for letters of intent has passed for 2024. The 2025 RFA will be released in January, 2025.
The Broderick Crawford Community-Research Partnership Awards
Frontiers and the Frontiers Community and Collaboration Core are pleased to announce the availability of theBroderick Crawford Community Research Partnership Awards to support the Development of new academic-community partnerships or to strengthen existing partnerships. These awards will be used to facilitate community-based activities that build trust and strengthen relationships between researchers, patient advocates, community members and/or community-based organizations.
Up to six awards issued annually; each award is up to $2,500.
About Broderick A. Crawford:
Broderick Crawford was the President and Executive Director of the NBC Community Development Corporation. With over 30 years of experience in health care and community advocacy, Broderick was a national leader for community voice in research. He served on the Recruitment Innovation Center Community Advisory Board and was a Co-Principal Investigator on a large National Institutes of Health funded RADx-UP grant project in 10 Kansas counties. Many of us were fortunate enough to call him a friend and colleague and he more than deserves this award to be named in his honor.
Application Materials
The Broderick Crawford Community Research Partnership Funding Mechanism is currently Closed. The deadline for letters of intent has passed for 2024. The 2025 RFA will be released in Fall 2024.
Inter-Institutional Pilot Project Awards
The National Center for Advancing Translational Sciences’ (NCATS) Clinical & Translational Science Award (CTSA) program seeks to develop and implement innovative solutions that will improve the efficiency, quality, and impact of the process for turning observations in the laboratory, clinic, and community into interventions that improve the health of individuals and communities.
The CTSA program supports a national network of medical research institutions that work together to speed the translation of research discovery into improved patient care. Eight CTSA institutions have joined together to form the Consortium of Rural States (CORES): The University of Utah Health, the University of New Mexico Health Sciences Center, Frontiers Clinical and Translational Science Institute, the University of Kentucky, the Translational Research Institute at the University of Arkansas for Medical Sciences, the University of Iowa, Dartmouth University, and Penn State University.
The purpose of this request for applications (RFA) is to promote multi-institutional collaboration across the CTSA consortium by funding innovative translational science research projects that involve two or more of these seven CTSA institutions. This pilot program is soliciting applications from faculty members at all career levels for translational science pilot projects that will exemplify the CTSA mission of “understanding a scientific or operational principle underlying a step of the translational process with the goal of developing generalizable principles to accelerate translational research.”
CORES Pilot Focus Areas
The CORES Inter‐Institutional Pilot Program will fund translational science projects aiming to identify and overcome barriers to the performance of translational research.
Pilots should articulate a clear translational research barrier(s) and propose an innovative plan to overcome or ameliorate the barrier (i.e., a translational science innovation). The proposed innovations should be broadly generalizable to many different translational research questions, and not specific to any one project or disease. Proposed projects should align with one of the following project scopes:
Develop:
|
New methodology, technology, tool, resource, or training paradigm that has generalizable application to an identified translational roadblock |
Demonstrate: |
New methodology, technology, tool, resource, or training paradigm to improve the effectiveness or efficiency of the translational process (including feasibility to support future clinical or translational science or research projects) |
Disseminate: |
Tools to effectively promote methodology, technology, tool, resource, or training paradigm that overcome an identified translational roadblock or improve the effectiveness or efficiency of the translational process into broader use |
In accordance with the National Institutes of Health (NIH) strategic plan and its commitment to increasing representation in research, funding emphasis for this RFA will be given to translational science proposals that address one of the following:
- Climate Change and Environmental Health
- Rural Health
- Maternal Health
- Health Equity for Underrepresented Populations
- For example, pediatric populations, older adults, people with disabilities and/or rare disorders, underrepresented racial/ethnic and/or sexual and gender minorities, rural populations or populations with low socio-economic status. Click here for more details.
Application Materials
The next iteration of the CORES Inter-institutional Pilot Award will be announced in Fall 2024.
Previous Application Materials
Trailblazer Awards
Frontiers offers Trailblazer Awards that provide funding to support targeted research.
Institute for Advancing Medical Innovation Trailblazer Awards
The Institute for Advancing Medical Innovation (IAMI) Trailblazer Award provides grant funding and other support for clinical and translational research across a broad range of scientific disciplines. The objective of this pilot program is to support new and innovative ideas that will lead to externally funded awards. The Frontiers IAMI Trailblazer Award addresses this goal by providing funds to help investigators carry out early-stage project development of novel drugs, devices, and diagnostics. The overall intent is to acquire research results that are disseminated in impactful publications, support successful extramural funding applications, and yield products to be entered into our product development pipeline.
Up to two awards are given annually for up to $25,000 each.
IAMI Research Focus Areas
Experimental Therapeutics Trials
Eligible research activities include a) clinical validation of a drug target; b) clinical pharmacology (e.g., drug metabolism, bioanalysis, pharmacokinetics, pharmacodynamics, pharmacogenomics, allometric scaling); c) clinical proof of concept of a novel therapeutic or a repurposed FDA-approved or abandoned drug. Eligible awardees must have demonstrated proof of principle in validated in vitro and/or in vivo preclinical models.
Drug and Medical Device Development
Eligible research activity includes high throughput screening; generation and optimization of small molecule lead candidates; discovery of macromolecule therapeutics; synthesis of sufficient quantities of active pharmaceutical ingredient required for animal testing; conduct of preclinical safety, pharmacokinetic and proof of principle studies in validated animal models of disease; formulation development (including analytical chemistry support); as well as creation of prototype medical devices as well as necessary device testing.
Biomarker Discovery and Validation
Eligible research activities include a) biospecimen collection; b) patient registry development; c) genetic, genomic, proteomic and metabolomic analysis of patient specimens, and d) analysis of patient specimens using established and investigational methods to discover and validate biomarkers of drug activity.
Entrepreneurship Activities Consistent with IAMI’s Mission
Eligible research activities defining the investment thesis for potential product development opportunities, including unmet medical need, proposed solution, market, competitive landscape, patent position and strategy, summary of existing data, product development and regulatory planning, marketing and licensing strategy, as well as support for obtaining key opinion leader input.
While not required, special consideration will be given to applications which address the CTSA priority of research into the needs of the rare disease community.
Application Materials
The deadline for letters of intent has passed for 2024. The 2025 RFA will be released in December, 2024.
Previous Application Materials
Biostatistics, Epidemiology and Research Design Trailblazer Award
The Biostatistics, Epidemiology, and Research Design (BERD) Trailblazer Award provides grant funding to support statistical, epidemiological, and data science investigations toward novel methods development that will improve clinical and translational research (CTR) inferences. BERD Trailblazer Awards support research projects for methods development for CTR.
One award is given annually for up to $20,000.
BERD Research Focus Areas
Frontiers BERD Trailblazer Awards support projects that address methodologies or analyses useful to the study of all diseases, and include academic disciplines such as biostatistics, epidemiology, bioinformatics, data science, and other quantitative areas that impact clinical and translational science.
Application Materials
The deadline for letters of intent has passed for 2024. The 2025 RFA will be released in December 2024.
Previous Application Materials
External Funding Opportunities
TOPMed Fellowship – Funding Opportunity Description
Over the last several decades, NHLBI has invested in creating a significant resource for research and development by supporting the creation of many observational, epidemiological, and longitudinal datasets related to heart, lung, blood and sleep phenotypes, with the aim of uncovering insights that may be leveraged toward novel therapeutic, interventional, or preventive strategies resulting in improved patient outcomes. In the past 10 years, the TOPMed program has generated a collection of genomic, epigenomic, transcriptomic, proteomic, and metabolomic data (see details at https://topmed.nhlbi.nih.gov/) from over 200,000 well-phenotyped individuals to enable detailed characterization of these study participants. This data is available for access by researchers in the BioDataCatalyst and dbGaP databases. Together, this multi-omics data coupled with clinical, imaging, EHR, and environmental data, present both unprecedented opportunities for data-driven discovery as well as challenges. Analyzing and combining these datasets are currently limited by both practical and conceptual constraints. With this fellowship program, TOPMed seeks to enable and accelerate AI/ML-driven mining of these rich datasets from diverse populations.
The goal of the TOPMed Fellowship program is to promote broad participation and engagement of early-career researchers in applying novel and innovative AI/ML approaches on data-focused research problems. The program will provide support for researchers who will leverage the trans-omics resources of TOPMed and beyond to gain access to training, data, and analytical tools needed to rapidly develop research skills required in the AI/ML field. It will also cultivate a community of computer scientists and data scientists with broad understanding of AI/ML to help drive scientific discovery in biomedical research and precision medicine through the informed use of AI/ML. The fellowship opportunities are aimed to facilitate the career advancement and/or transition of scientists to the next steps in their scientific careers and to develop a cadre of diverse scientists capable of applying AI/ML approaches to address challenging research questions in areas of HLBS, including Women’s Health Research and bias in AI/ML algorithms or data.
The NHLBI recognizes a unique and compelling need for its precision medicine program to promote inclusive excellence in genomics and its data sciences research workforce. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support (see NOT-OD-20-031).
Applicants need to focus on the area within the NHLBI’s mission and propose to use existing or up- coming data to conduct discovery research. In addition, applicants are encouraged either to use an AI/ML method as one of their main analytic tools in their research plan or have an AI/ML training plan outside the main research plan. TOPMed fellows are encouraged to use TOPMed data as either the primary or secondary dataset in their proposals. Examples of relevant topic areas and research approaches include but are not limited to:
- AI/ML models to analyze multi-omics data along with other phenotypic and clinical data;
- Novel approaches to better understand and predict women's health issues with special focus on lifespan events such as pregnancy and menopause;
- Evaluate advance and limitations of AI/ML methods in applications for HLBS research;
- Leveraging genomics and longitudinal clinical data to understand susceptibility, differential risk, and need for intensive intervention of HLBS disease.
To apply, visit the TOPMed website at https://topmed.nhlbi.nih.gov/2024-topmed-fellowship to create an applicant account.
KEY DATES
- Solicitation Open Date: August 9, 2024
- Informational Webinar Session: September 5, 2024, at 3:00pm ET.
- Frequently Asked Questions Posted: September 10, 2024
- Proposal Due Date: October 29, 2024, 5:00PM EDT
- Scientific Review Meeting: Week of December 2, 2024
- Award Notification: February 15, 2025
For questions, please contact the TOPMed Administrative Coordinating Center at topmed-admin@westat.com.
Previously Funded Projects
Eligibility
Funding opportunities are open to principal investigators who are eligible to receive federal funding and employed by any Frontiers partner institution:
- Children's Mercy Kansas City
- Kansas City University (all campuses)
- Kansas State University (all campuses)
- Saint Luke's Health System
- University of Kansas
- University of Kansas Medical Center (all campuses)
- The University of Kansas Health System
- University of Missouri-Kansas City
Academic applicants are encouraged to collaborate with community organizations to develop an application.
Early to mid-career investigators are encouraged to apply. Established principal investigators may apply but should strongly justify how the pilot project is a new line of inquiry.
Principal Investigators are allowed to apply for more than one funding mechanism but will only be allowed to accept one award annually. Applicants may serve as PI on only one application but may be included as collaborators on any number of applications.
Volunteer faculty, residents, fellows, or graduate students are generally not eligible to serve as principal investigators. United States citizens, non-citizen nationals, or those who have legal admission as a permanent resident are eligible. However, any questions regarding eligibility should be addressed to individual institutional grants management offices before submission.
Citing Frontiers
All publications and presentations need to acknowledge NIH grant support arising from any research project that used Frontiers resources. Please use the correct citation language below depending on when you received support and on the type of support received.
The University of Kansas received its initial Clinical and Translational Science Award (CTSA) from the National Institutes of Health (NIH) which provided funding from July 1, 2011 through June 30, 2016. The CTSA program transferred from the National Center of Research Resources (NCRR) to the National Center for Advancing Translational Sciences (NCATS) in December 2011. The University of Kansas received its second CTSA in September 2017 from NCATS with the award period ending July 2022. The University of Kansas received its renewed CTSA in July 2022 from NCATS with the award period ending June 2027.
Support received between 2022 - 2027:
Support (Full or partial support from the CTSA)
Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under the Award Number UL1TR002366. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Mentored Career Development Awards (KL2)
Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under the Award Number KL2TR002367. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Pre- and Post-doctoral Trainee Awards (TL1)
Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under the Award Number TL1TR002368. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Support received between 2017-2022:
Support (Full or partial support from the CTSA)
This work was supported by a CTSA grant from NCATS awarded to the University of Kansas for Frontiers: University of Kansas Clinical and Translational Science Institute (# UL1TR002366) The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NCATS.
Mentored Career Development Awards (KL2)
This work was supported by a CTSA grant from NCATS awarded to the University of Kansas for Frontiers: University of Kansas Clinical and Translational Science Institute (# KL2TR002367). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NCATS.
Pre- and Post-doctoral Trainee Awards (TL1)
This work was supported by a CTSA grant from NCATS awarded to the University of Kansas for Frontiers: University of Kansas Clinical and Translational Science Institute (# TL1TR002368). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NCATS.
Support received between 2011-2016:
Support (Full or partial support from the CTSA)
This work was supported by a CTSA grant from NCATS awarded to the University of Kansas Medical Center for Frontiers: The Heartland Institute for Clinical and Translational Research (# UL1TR000001). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NCATS.
Mentored Career Development Awards (KL2)
This work was supported by a CTSA grant from NCATS awarded to the University of Kansas Medical Center for Frontiers: The Heartland Institute for Clinical and Translational Research (# KL2TR000119). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NCATS.
Pre- and Post-doctoral Trainee Award (TL1)
This work was supported by a CTSA grant from NCATS awarded to the University of Kansas Medical Center for Frontiers: The Heartland Institute for Clinical and Translational Research (# TL1TR000120). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NCATS.